Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Glenmark Pharmaceuticals
Strong Core business growth to support earning momentum
Glenmark over the last few quarters has seen a revival in the financials
driven by the strong growth in its core business with healthy growth
coming in from across all the geographic segments of the company. Our
conservative estimate sees a CAGR of 19% over the next 3 years in its
base business driven by the sustained high growth in the domestic
formulation segment and turnaround of the US operations owing to the
flurry of ANDA approvals (14 approvals from Apr-Dec 2010) and niche
product launches. Further glenmark is expected to record a CAGR of
28% over FY10-13E in the other markets where it is present considering
the company’s significant investments in these markets and expected
high growth in the Latin American market and other Semi-Regulated
markets.